Another large-scale trial of preventive tuberculosis therapy has ended with disappointing results.
Untargeted and communitywide distribution of prevention drugs does not reduce the prevalence of tuberculosis, the seven-year study conducted among South Africa’s gold mine communities has found, Plus News reports.
The study, dubbed Thibela, is the second of its kind to arrive at such findings over the past six months. In October 2011, results of a similar trial conducted among 963,000 people in South Africa and Zambia also showed that community-based tuberculosis testing did not reduce prevalence of new cases.
Researchers involved in the two studies said they are now evaluating their data to determine why the trials failed to reduce prevalence of tuberculosis cases. Findings from these further evaluations are expected to be released at the South Africa tuberculosis conference in June.
Thibela and the earlier study, ZAMSTAR, are part of the Consortium to Respond Effectively to the AIDS/TB Epidemic, which receives funding from the Bill & Melinda Gates Foundation.
Read more news about development aid online, and subscribe to The Development Newswire to receive top international development headlines from the world’s leading donors, news sources and opinion leaders — emailed to you FREE every business day.